Acuta Capital Partners’s Aclaris Therapeutics ACRS Stock Holding History

Acuta Capital Partners’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-121,692	Closed	-$834K	–	40
2023 Q3	$834K	Hold	121,692	–	–	0.56%	33
2023 Q2	$1.26M	Sell	121,692 -148	-0.1%	-$1.34K	0.86%	25
2023 Q1	$986K	Sell	121,840 -133,160	-52%	-$1.69M	0.73%	21
2022 Q4	$4.02M	Buy	255,000 +94,165	+59%	+$1.51M	2.47%	18
2022 Q3	$2.53M	Sell	160,835 -32,000	-17%	-$504K	1.09%	24
2022 Q2	$2.69M	Sell	192,835 -24,765	-11%	-$347K	1.5%	23
2022 Q1	$3.75M	Buy	217,600 +119,600	+122%	+$1.63M	1.75%	21
2021 Q4	$1.43M	Sell	98,000 -42,839	-30%	-$649K	0.6%	31
2021 Q3	$2.54M	Sell	140,839 -34,161	-20%	-$548K	0.89%	30
2021 Q2	$3.07M	Sell	175,000 -142,730	-45%	-$3.24M	1.23%	28
2021 Q1	$8.01M	Buy	+317,730	New	+$6.21M	2.89%	12
2018 Q1	–	Sell	-92,500	Closed	-$2.28M	–	62
2017 Q4	$2.28M	Buy	+92,500	New	+$2.25M	0.43%	33
2017 Q3	–	Sell	-90,000	Closed	-$2.44M	–	65
2017 Q2	$2.44M	Sell	90,000 -110,000	-55%	-$2.99M	0.68%	27
2017 Q1	$5.96M	Sell	200,000 -172,753	-46%	-$4.98M	1.41%	19
2016 Q4	$10.1M	Buy	+372,753	New	+$9.5M	3.76%	10

Other funds holding ACRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Acuta Capital Partners's ACRS Position: Q4 2023 in Review

Acuta Capital Partners sold out of Aclaris Therapeutics (ACRS) in Q4 2023, closing a stake of 121,692 shares — an estimated $834K sold.

Acuta Capital Partners first reported a position in ACRS in Q4 2016 and held it in 15 quarters. The position peaked at $10.1M in Q4 2016. 107 funds tracked by Wall St. Rank hold ACRS as of Q4 2023.

Acuta Capital Partners reported no remaining Aclaris Therapeutics position as of Q4 2023 after selling out during the quarter.
Acuta Capital Partners sold 121,692 Aclaris Therapeutics shares in Q4 2023, an estimated $834K.
Acuta Capital Partners first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 15 quarters.
Acuta Capital Partners's Aclaris Therapeutics position peaked at $10.1M in Q4 2016.
107 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2023.

Based on Acuta Capital Partners's 13F filing for Q4 2023, filed 14 Feb 2024.